目的 基于數(shù)據(jù)挖掘，分析以黃芪為核心的方劑治療氣虛血瘀型卒中的用藥規(guī)律，運用網(wǎng)絡(luò)藥理學(xué)探討含黃芪核心藥物組治療該病的作用機制。方法 以中國學(xué)術(shù)期刊全文數(shù)據(jù)庫、萬方數(shù)據(jù)知識服務(wù)平臺、維普生物醫(yī)學(xué)數(shù)據(jù)庫、中國生物醫(yī)學(xué)文獻數(shù)據(jù)庫、PubMed、Web of Science等中英文數(shù)據(jù)庫收錄的相關(guān)文獻為數(shù)據(jù)來源，使用Microsoft Excel 2019建立數(shù)據(jù)庫，基于Apriori算法進行關(guān)聯(lián)規(guī)則分析，將滿足支持度≥0.55、置信度≥0.9藥對作為黃芪核心藥物組，通過網(wǎng)絡(luò)藥理學(xué)探究黃芪核心藥物組治療該病癥的作用機制并借助分子對接加以驗證。結(jié)果 最終納入86首目標方劑，涉及138味中藥，累計使用頻次908次，關(guān)聯(lián)規(guī)則分析結(jié)果表明黃芪與川芎、當歸、地龍、紅花、赤芍具有強關(guān)聯(lián)性，以這6味中藥組成的核心藥物組共含有89種成分和165個潛在靶點，其中107個潛在靶點分布在神經(jīng)系統(tǒng)，關(guān)鍵靶點包含絲氨酸/蘇氨酸激酶1 （AKT1）、血清白蛋白（ALB）、腫瘤壞死因子（TNF）、白細胞介素-6 （IL6）、白細胞介素-1β （IL1B）等。基因本體（GO）功能分析主要涉及調(diào)節(jié)能量代謝、炎癥應(yīng)答、細胞凋亡等生物過程；京都基因與基因組百科全書（KEGG）通路富集分析中磷脂酰肌醇3-激酶-蛋白激酶（PI3K-Akt）、MAPK、IL-17、TNF等通路與核心藥物組治療氣虛血瘀型卒中密切相關(guān)。分子對接結(jié)果顯示豆甾醇、β-谷甾醇、槲皮素及漢黃芩素與關(guān)鍵靶蛋白具有較高的結(jié)合活性。結(jié)論 該研究歸納總結(jié)了含黃芪方劑治療氣虛血瘀型卒中的用藥配伍規(guī)律，得到1個黃芪核心藥物組，并且在分子水平揭示了黃芪核心藥物組治療該病癥的機制，為后續(xù)含黃芪方劑治療該病癥的開發(fā)提供了數(shù)據(jù)支撐。

Objective Based on data mining, the dosing regularity of Astragali Radix as the core treatment for apoplexy with syndrome of qi deficiency and blood stasis was analyzed, and the network pharmacology was used to elucidate the mechanism of the core drug group containing Astragali Radix in the treatment of this disease. Methods Relevant literature collected by CNKI, Wanfang, VIP, CBM, PubMed and Web of Science were used as data sources, and the database was established by Microsoft Excel 2019. Based on Apriori algorithm for association rule, the drug pair that satisfied support ≥ 0.55 and confidence ≥ 0.9 as the core drug group containing Astragali Radix. The mechanism of the Astragali Radix core drug group for the treatment of this disease was investigated through network pharmacology and validated with molecular docking. Results The results showed that a total of 86 target formulas involving 138 TCMs were screened, with a cumulative frequency of 908 uses. The analysis of association rules showed that Astragali Radix was strongly associated with Chuanxiong Rhizoma, Angelicae Sinensis Radix, Pheretima, Carthami Flos, and Paeoniae Radix Rubra, and the core drug group with these six herbs contained 89 ingredients and 165 potential targets, of which 107 potential targets were distributed in the nervous system, and the key targets contained serine/threonine kinase 1 (AKT1), serum albumin (ALB), tumor necrosis factor (TNF), leukocyte interleukin-6 (IL6), interleukin-1β (IL1B), etc. GO functional analysis mainly involved the regulation of biological processes such as energy metabolism, inflammatory response, and apoptosis. Phosphatidylinositol 3-kinase-protein kinase (PI3K-Akt), MAPK, IL-17, and TNF pathways in KEGG enrichment analysis were closely related to the treatment of apoplexy with syndrome of qi deficiency and blood stasis. Molecular docking results showed that stigmasterol, β-sitosterol, quercetin and wogonin had high docking activities with key target proteins. Conclusions This study summarized the dosing regularity of prescriptions containing Astragali Radix in the treatment of apoplexy with syndrome of qi deficiency and blood stasis, and revealed the mechanism of the core drug group containing Astragali Radix in the treatment of this disease at the molecular level, which provides data support for the subsequent development of prescriptions containing Astragali Radix in the treatment of this disease.

R285.5

廣西中醫(yī)藥大學(xué)“桂派杏林青年英才”培養(yǎng)項目（2022C032）;廣西高等學(xué)校千名中青年骨干教師培育計劃項目（桂教教師〔2022〕60號）;廣西中醫(yī)藥大學(xué)橫向課題（H2021019）;中藥學(xué)廣西一流學(xué)科（桂教科研〔2018〕12號）;壯瑤藥協(xié)同創(chuàng)新中心（桂教科研〔2013〕20號）;廣西壯瑤藥重點實驗室（桂科基字〔2014〕32號）;廣西八桂學(xué)者中藥創(chuàng)新理論與藥效研究項目（J13162）;廣西重點學(xué)科壯藥學(xué)（桂教科研〔2013〕16號）